The results of randomized clinical trials were analyzed. The therapy with an ACE inhibitor zofenopril in patients with cardiovascular disease
resulted to reduction of cardiovascular complications and mortality risk. Zofenopril was safe and well-tolerated patients. Ongoing
zofenopril trials are also reviewed.

The functional condition of endothelium is investigated at 36 patients with arterial hypertension II-III of a stage (aged 44-80 years) during 3
monthly treatments by fixed combination metoprolol succinate + felodipine (Logimax). Blood pressure (BP) was monitored for 24 hours.
Endothelial vasodilatation function and thickness of a complex intimae - media were evaluated with ultrasonic duplex scanning of arteries. It has
been revealed reduced endothelium-dependent vasodilatation and structural remodeling of peripheral arteries in elderly hypertensives. Alongside
with high antihypertensive activity, indapamid retard positively influenced on structural and functional characteristics of humeral arteries.

Angiotensin-converting enzyme inhibitor is one of basic antihypertensive drugs for treatment of arterial hypertension at first stages of
the disease. The review summarizes the data on different ACE inhibitors.

The article summarizes the available data on amlodipin in hypertensive patients of high cardiovascular risk. The results of studies
demonstrate strong and long-lasting antihypertensive effect of ramipril. Moreover, amlodipin treatment decreases cardiovascular events
rate, damage of target organs and atherosclerosis progression. Amlodipin shows both high efficacy and good safety. All this properties
make amlodipin extremely attractive for the everyday practice.

Aim: To evaluate efficacy and tolerance of a compound drug Co-renitec combining an ACE inhibitor enalapril maleate and diuretic
hydrochlorothiazide. Co-renitec taken for 16 weeks in patients with essential hypertension (EH). Material and methods: 28 patients
with EH (16 males and 12 females aged 47-74 years) of mean duration 132 years. Blood pressure (BP) was monitored for 24 hours
with the device SL 90207 (SpaceLabs Medical, USA). Microalbuminuria (MAU) was estimated with the use of immunoturbodimetric
test. Results: By 24-hour monitoring, Co-renitec reduced day BP by 15/9 - 3/2 mm Hg, nocturnal BP lowered by 19/12 - 3/2 mmHg,
pulse pressure also fell. Coefficient T/P was 53% for systolic BP (SBP) and 60% for diastolic BP (DBP). The target BP was reached in
70% patients. Co-renitec significantly decreased MAU, albumines excretion normalized in 46% patients. Conclusion: Co-renitec lowers
both day and nocturnal blood pressure, improves 24-h rhythm of BP, has a positive effect on the kidneys. This allows its recommendation
as a first-line drug in patients with moderate and severe EH.

Problems of diagnostics and treatment of ischemic renal disease (atherosclerotic stenosis of renal arteries) at patients with diabetes mellitus
are discussed.

Many large studies have provided strong evidence that there is an association of elevated BP with a risk for cardiovascular events (CVE),
such as stroke, myocardial infarction and heart failure. But none of the studies has indicated that a drug is more effective than another one
in reducing the risk for CVE and death. The article summarizes the available data on ramipril in hypertensive patients of high cardiovascular
risk. The results of studies demonstrate strong and long-lasting antihypertensive effect of losartan. Moreover, losartan treatment
decreases cardiovascular events rate, damage of target organs, atherosclerosis progression and new cases of diabetes mellitus. Losartan
shows both high efficacy and low adverse event rate.

Aim: this study the changes of blood pressure (BP), heart rate variability (HRV) characteristics, average weighed rhythmogram variation
(AWRV) and QTc in patients with metabolic syndrome (MC) and arterial hypertension (AH) before and after therapy of betablocker,
metformin and their combination. Materials: 51 patients with МС and AH were enrolled in the study. The patients were randomization on 3 groups:
the monotherapy of nebivolol (N) 5 mg/days (n=18), the monotherapy of metformin (M) 1700 mg/days (n=15) and nebivolol+metformin
combination therapy (N+M) (n=18). The estimated variables included of BP, HRV, AWRV and QTc before and after 24 weeks of
the treatment. Results: after 24 weeks of the N treatment QTc interval change from 44823 ms to 43317ms (p<0.05), AWRV change from 784198
ms to 9355315 (p>0.05). Treatment of M changes AWRV from 872234 ms to 761195 (p>0.05), QTc from
44825 ms to 43427 ms (p<0.05). Treatment of the combination N+M therapy did not significant dynamics of AWRV
and QTc. Conclusion: The conclusion: the nebivolol monotherapy increased HRV. Metformin monotherapy and combination N+M therapy
does not significant change HRV. The monotherapy of N or M leads to reduction of interval QTc.

In our days big attention is drawn to safe drug therapy. It importance is associated with great prevalence of medical products side
effects and consequences, high economic expenses for their correction. Knowing specific features of adverse drug reactions in different
groups of patients it could be possible to decrease their prevalence and magnitude.

The articles represents analysis of monitoring of epidemiological situation and dynamics of statistical parameters of health of the population
connected with arterial hypertension from the standpoint of realization of measures on fulfillment of the National program of
prophylaxis and treatment of arterial hypertension in Ukraine (1999-2007 year).